Related Experiment Video
Updated: Feb 18, 2026
08:34
Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
Published on: November 18, 2018
7.7K
[Pulmonary hypertension and pregnancy]
Eleni Diamanti1, David Baud2, John-David Aubert1
1Service de pneumologie, CHUV, 1011 Lausanne.
Revue Medicale Suisse
|November 17, 2017
Summary
Pregnancy with pulmonary hypertension poses high risks for both mother and fetus, necessitating contraception for women of reproductive age. Those continuing pregnancy require specialized multidisciplinary care and prompt treatment.
Area of Science:
- Cardiology
- Obstetrics
- Pulmonary Medicine
Background:
- Pulmonary hypertension significantly increases maternal and fetal mortality risks during pregnancy.
- Pregnancy is strongly discouraged for women with pulmonary hypertension.
Purpose of the Study:
- To outline management strategies for pregnant patients with pulmonary hypertension.
- To emphasize the need for specialized care and timely interventions.
Main Methods:
- Review of existing literature and clinical guidelines.
- Emphasis on multidisciplinary team approach and specialized centers.
- Consideration of specific treatments like intravenous prostacyclin for deterioration.
Main Results:
- High mortality rates underscore the risks associated with pregnancy and pulmonary hypertension.
- Multidisciplinary care and specialized centers are crucial for managing these high-risk pregnancies.
- Early prostacyclin administration is a key consideration in clinical deterioration.
Conclusions:
- Pregnancy in women with pulmonary hypertension demands extreme caution, specialized management, and immediate treatment decisions.
- Contraception is advised for women of reproductive age with pulmonary hypertension.
- Optimal delivery timing and methods remain areas for further discussion and research.
More Related Videos
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
681
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
681
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
492
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
492
01:29Pulmonary Embolism I: Introduction
897
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
897
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
649
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
649
01:19Mitral Valve Prolapse III: Nursing Management
430
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
430
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
529
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
529